- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02542644
Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT
Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following Descemet's Membrane Endothelial Keratoplasty Using Ultra-high Resolution Optical Coherence Tomography
Fuchs endothelial corneal dystrophy (FECD) is a progressive disease characterized by the loss of endothelial cells, thickening of Descemet's membrane and deposition of extracellular matrix in the form of guttae. This result in failure of the endothelium to support corneal deturgescence leading to corneal edema. Affected patients complain about blurred vision at early stages of the disease which can progress to blindness. The pathophysiology of the disease is still unclear, but several studies point towards a genetic susceptibility. Additional risk factors that have been identified are female sex, smoking and older age.
While for a long time penetrating keratoplasty (PKP) was the only therapy available for affected patients, in the recent years less invasive methods such as descemet's membrane endothelial keratoplasty (DMEK) have been developed. In DMEK, only the Descemet's membrane and the endothelium is removed and replaced with the corresponding parts from a donor's cornea. For FECD, this brings the advantage that only the diseased part of the cornea is replaced. Graft detachment has been identified as the main complication following DMEK.
In the investigators' study, an ultra high resolution OCT system will be used to detect graft detachment in patients with FECD after DMEK. With this technique, even small detachments can be visualized. The area of graft detachment will be evaluated at predefined time points after surgery and correlated to visual acuity. A follow-up of one year will be performed in order to investigate the predictive value of graft adherence status at several time points for visual outcome.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1140
- Vienna Institute for Research in Ocular Surgery (VIROS)
-
Vienna, Austria, 1090
- Medical University Vienna, Department of Clinical Pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged over 18 years scheduled for primary DMEK because of Fuchs' Endothelial Dystrophy
Exclusion Criteria:
- Any disease inhibiting OCT acquisition; such as blepharospasm, severe tremor or immobility
- Any previous intraocular surgery other than cataract extraction
- Previous clinically significant ocular trauma in the study eye, as judged by the investigator
- Pregnancy, planed pregnancy, or lactating
- Appointment of a custodian
- Progressive retinal disease
- History or presence of glaucoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Patients with Fuchs endothelial dystrophy scheduled for DMEK
|
The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea. A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in best corrected visual acuity at 12 months compared to baseline using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Time Frame: 1-2 days, 1 week, 1 month, 6 months and 12 months after DMEK
|
Visual acuity will be measured using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
|
1-2 days, 1 week, 1 month, 6 months and 12 months after DMEK
|
Area of attached graft after DMEK
Time Frame: 12 months after DMEK
|
12 months after DMEK
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients in which rebubbling has to be performed
Time Frame: 12 months
|
12 months
|
|
Number of patients needing retreatment
Time Frame: 12 months
|
12 months
|
|
Best corrected visual acuity at 6 months using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
Time Frame: 6 months
|
Visual acuity will be measured using a standardized protocol with the Early Treatment Diabetic Retinopathy (ETDRS) charts (4 meters).
|
6 months
|
Central corneal thickness
Time Frame: 12 months
|
12 months
|
|
Corneal endothelial cell count
Time Frame: 12 months
|
12 months
|
|
Demographic risk factors such as age
Time Frame: 12 months
|
12 months
|
|
Demographic risk factors such as gender
Time Frame: 12 months
|
12 months
|
|
Demographic risk factors, such as family history
Time Frame: 12 months
|
12 months
|
|
Demographic risk factors, such as smoking status
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Katarzyna Witkowska, MD, Department of Clinical Pharmacology, Medical University of Vienna
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPHT-013015
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fuchs' Endothelial Dystrophy
-
Kowa Research Institute, Inc.CompletedFuchs' Endothelial Corneal DystrophyUnited States, Australia, Germany, Spain, Denmark
-
Legacy Health SystemDevers Eye Institute; Lions Eye Bank of Oregon Vision Research Laboratory; Fischer...UnknownFuchs' Corneal Endothelial DystrophyUnited States
-
Massachusetts Eye and Ear InfirmaryRecruitingFuchs' Endothelial Corneal DystrophyUnited States
-
State University of New York at BuffaloActive, not recruitingFuchs DystrophyUnited States
-
EmmecellRecruitingEndothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial DecompensationUnited States
-
Charite University, Berlin, GermanyUnknownEndothelial Dysfunction | Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyGermany
-
Cornea Research Foundation of AmericaCompletedBullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyUnited States
-
Trefoil Therapeutics, Inc.CompletedEndothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal DystrophyUnited States
-
Centre Hospitalier Universitaire de Saint EtienneKyoto University, Graduate School of MedicineCompletedFuchs Endothelial Corneal DystrophyFrance
-
Centre Hospitalier Régional Metz-ThionvilleCompletedPseudophakic Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Descemet Membrane Endothelial Keratoplasty | Graft DetachmentFrance
Clinical Trials on Ultrahigh resolution Spectral Domain OCT
-
Medical University of ViennaRecruiting
-
Medical University of ViennaEnrolling by invitationGlaucoma | Cataract | Meibomian Gland Dysfunction | Aniridia | Corneal Transplantation | Acanthamoeba Keratitis | Demodicosis | Conjunctival PathologiesAustria
-
University Hospital Inselspital, BerneRecruitingGlaucoma | Macular Degeneration | Uveitis | Diabetic Retinopathy | Diabetic Macular Edema | Macular Edema | Retinal Vein Occlusion | Optic Nerve Diseases | Retinal Detachment | Macular Disease | Retinal Disease | Retinal Neovascularization | Retinal Artery Occlusion | Hypertensive Retinopathy | Retinal Edema | Retinal DystrophySwitzerland
-
Wills EyeCompleted
-
Duke UniversityAlzheimer's Association; Duke-NUS Graduate Medical School; Duke Institute for...CompletedMild Cognitive Impairment | Mild to Moderate Cognitive ImpairmentUnited States
-
Yonsei UniversityUnknownHealthy | Myopia | HypermetropiaKorea, Republic of
-
Moorfields Eye Hospital NHS Foundation TrustCompletedRetinal Diseases | Vitreous Diseases | Choroidal DiseasesUnited Kingdom
-
Johns Hopkins UniversityNational Eye Institute (NEI)RecruitingRetinal Vascular Disorder | Diabetic Retinopathy | Retinal Vein Occlusion | Hypertension,EssentialUnited States
-
Fondation Ophtalmologique Adolphe de RothschildCompletedRetina | Tomography, Optical CoherenceFrance